207 related articles for article (PubMed ID: 34915417)
1. Non-coding RNAs-EZH2 regulatory mechanisms in cervical cancer: The current state of knowledge.
Zheng J; Chen L
Biomed Pharmacother; 2022 Feb; 146():112123. PubMed ID: 34915417
[TBL] [Abstract][Full Text] [Related]
2. Emerging Roles of LncRNAs in the EZH2-regulated Oncogenic Network.
Hao A; Wang Y; Stovall DB; Wang Y; Sui G
Int J Biol Sci; 2021; 17(13):3268-3280. PubMed ID: 34512145
[TBL] [Abstract][Full Text] [Related]
3. The long and short non-coding RNAs modulating EZH2 signaling in cancer.
Mirzaei S; Gholami MH; Hushmandi K; Hashemi F; Zabolian A; Canadas I; Zarrabi A; Nabavi N; Aref AR; Crea F; Wang Y; Ashrafizadeh M; Kumar AP
J Hematol Oncol; 2022 Mar; 15(1):18. PubMed ID: 35236381
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA LINC01535 promotes cervical cancer progression via targeting the miR-214/EZH2 feedback loop.
Song H; Liu Y; Jin X; Liu Y; Yang Y; Li L; Wang X; Li G
J Cell Mol Med; 2019 Sep; 23(9):6098-6111. PubMed ID: 31273925
[TBL] [Abstract][Full Text] [Related]
5. EZH2 RIP-seq Identifies Tissue-specific Long Non-coding RNAs.
Wang Y; Xie Y; Li L; He Y; Zheng D; Yu P; Yu L; Tang L; Wang Y; Wang Z
Curr Gene Ther; 2018; 18(5):275-285. PubMed ID: 30295189
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-137 is negatively associated with clinical outcome and regulates tumor development through EZH2 in cervical cancer.
Zhang H; Yan T; Liu Z; Wang J; Lu Y; Li D; Liang W
J Cell Biochem; 2018 Jan; 119(1):938-947. PubMed ID: 28681918
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer.
Sun NX; Ye C; Zhao Q; Zhang Q; Xu C; Wang SB; Jin ZJ; Sun SH; Wang F; Li W
PLoS One; 2014; 9(7):e100340. PubMed ID: 25007342
[TBL] [Abstract][Full Text] [Related]
8. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
Chen Q; Zheng PS; Yang WT
Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
[TBL] [Abstract][Full Text] [Related]
9. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
10. LncRNA SNHG8 accelerates proliferation and inhibits apoptosis in HPV-induced cervical cancer through recruiting EZH2 to epigenetically silence RECK expression.
Qu X; Li Y; Wang L; Yuan N; Ma M; Chen Y
J Cell Biochem; 2020 Oct; 121(10):4120-4129. PubMed ID: 31961005
[TBL] [Abstract][Full Text] [Related]
11. Tetraarsenic oxide affects non-coding RNA transcriptome through deregulating polycomb complexes in MCF7 cells.
Jeong J; Hamza MT; Kang K; Jo DS; Bae IJ; Kim D; Cho DH; Bunch H
Adv Biol Regul; 2021 May; 80():100809. PubMed ID: 33932728
[TBL] [Abstract][Full Text] [Related]
12. EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
Yan KS; Lin CY; Liao TW; Peng CM; Lee SC; Liu YJ; Chan WP; Chou RH
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561778
[TBL] [Abstract][Full Text] [Related]
13. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
[TBL] [Abstract][Full Text] [Related]
14. MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10.
Qi Y; Ooi HS; Wu J; Chen J; Zhang X; Tan S; Yu Q; Li YY; Kang Y; Li H; Xiong Z; Zhu T; Liu B; Shao Z; Zhao X
Oncotarget; 2016 Mar; 7(11):12693-703. PubMed ID: 26871474
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2.
Chen XJ; An N
J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
[TBL] [Abstract][Full Text] [Related]
16. LINP1 promotes the progression of cervical cancer by scaffolding EZH2, LSD1, and DNMT1 to inhibit the expression of KLF2 and PRSS8.
Wu L; Gong Y; Yan T; Zhang H
Biochem Cell Biol; 2020 Oct; 98(5):591-599. PubMed ID: 32348690
[TBL] [Abstract][Full Text] [Related]
17. Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers.
Wan Z; Jiang H; Li L; Zhu S; Hou J; Yu Y
Bioorg Med Chem; 2020 Apr; 28(7):115379. PubMed ID: 32098708
[TBL] [Abstract][Full Text] [Related]
18. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
19. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
20. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
